Instant Access

Ensuring Compliance Of Your Bioanalytical Method Validation With The 2013 FDA Draft Guidance

4448
Duration75 Minutes
Brian Kirk
Instructor

Brian Kirk

View profile

The Bioanalytical Method Validation (Draft Guidance 2013) represents the Food and Drug Administration’s current thinking on this topic and was published in September 2013. Since then, almost all regulated bioanalytical methods have been validated based on this guidance. This guidance provides assistance to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements in developing bioanalytical method validation information used in human clinical pharmacology, bioavailability (BA), and bioequivalence (BE) studies requiring pharmacokinetic (PK) evaluation. This guidance also applies to bioanalytical methods used for non-human pharmacology/toxicology studies and preclinical studies. This webinar will focus on the bioanalytical method validation to quantify drugs in biological matrices using LC/MS/MS.

Course Objectives:

• Understand the basic FDA guidelines for method validation described in the 2013 Draft GFI Document.
• Understand the significance of a bioanalytical method validation and its applicability to different aspects of drug development.
• Understand how to interpret the Draft Guidance and use it to establish validation parameters and acceptance limits.
• Understand the difference between a full, partial and cross-validation.
• Know how to apply the bioanalytical method validation to testing for routine drug analysis situations.
• Understand the basics of how to draft an SOP describing the Bioanalytical Method Validation process.

Course Outline:

• FDA guidelines for bioanalytical method validation.
• Learning from the Crystal City FDA/Industry conference report.                        
• Logistics of validation.
• Development of a master plan and SOP for validation.
• Preparation and use of reference standards and equipment.
• Defining parameters and acceptance limits.
• Defining validation experiments.
• Considerations for Microbiological and Ligand-binding Assays.
• To re-validate or not after method changes
• Transferring and using the method for routine analysis.

What You Get:

•  Training Materials
•  Live Q&A Session with our Expert
•  Participation Certificate
•  Access to Signup Community (Optional)
•  Reward Points

Who Will Benefit:

• Managers and analysts in bioanalytical laboratories
• QA managers and personnel
• Validation specialists
• Consultants, scientists, technologists, and engineers in the pharmaceutical industry.
• Bioanalytical scientists
• Biotech R&D staff
• Outsourcing Professionals
• Biopharmaceutical Consultants


Course Description:


The Bioanalytical Method Validation (Draft Guidance 2013) represents the Food and Drug Administration’s current thinking on this topic and was published in September 2013. Since then, almost all regulated bioanalytical methods have been validated based on this guidance. This guidance provides assistance to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements in developing bioanalytical method validation information used in human clinical pharmacology, bioavailability (BA), and bioequivalence (BE) studies requiring pharmacokinetic (PK) evaluation. This guidance also applies to bioanalytical methods used for non-human pharmacology/toxicology studies and preclinical studies. This webinar will focus on the bioanalytical method validation to quantify drugs in biological matrices using LC/MS/MS.

Course Objective:


  • Understand the basic FDA guidelines for method validation described in the 2013 Draft GFI Document.
  • Understand the significance of a bioanalytical method validation and its applicability to different aspects of drug development.
  • Understand how to interpret the Draft Guidance and use it to establish validation parameters and acceptance limits.
  • Understand the difference between a full, partial and cross-validation.
  • Know how to apply the bioanalytical method validation to testing for routine drug analysis situations.
  • Understand the basics of how to draft an SOP describing the Bioanalytical Method Validation process.

Course Outline:


Topics covered include:
  • FDA guidelines for bioanalytical method validation.
  • Learning from the Crystal City FDA/Industry conference report.                         
  • Logistics of validation.
  • Development of a master plan and SOP for validation.
  • Preparation and use of reference standards and equipment.
  • Defining parameters and acceptance limits.
  • Defining validation experiments.
  • Considerations for Microbiological and Ligand-binding Assays.
  • To re-validate or not after method changes
  • Transferring and using the method for routine analysis.

Target Audience:


  • Managers and analysts in bioanalytical laboratories
  • QA managers and personnel
  • Validation specialists
  • Consultants, scientists, technologists, and engineers in the pharmaceutical industry.
  • Bioanalytical scientists
  • Biotech R&D staff
  • Outsourcing Professionals
  • Biopharmaceutical Consultants 
Please reach us at 1-888-844-8963 for any further assistance or if you wish to register

100% MONEY BACK GUARANTEED

Refund / Cancellation policy

Get In Touch

Subject : Ensuring Compliance Of Your Bioanalytical Method Validation With The 2013 FDA Draft Guidance


Similar Trainings

Analyzing Assay Validation for Clinical Diagnostics
Life Sciences Clinical | Biotechnology | Laboratory
Get Instant Access 60 Minutes
View Program
General Data Protection Regulation (GDPR): Compliance for Clinical Trials
Life Sciences Clinical | Biotechnology | Laboratory
Get Instant Access 60 Minutes
View Program
Protocol Deviations: Documenting, Managing, and Reporting
Life Sciences Clinical | Biotechnology | Laboratory
Get Instant Access 60 Minutes
View Program
Adverse Event Reporting Understanding Regulatory Reporting Requirements
Life Sciences Clinical | Biotechnology | Laboratory
Get Instant Access 60 Minutes
View Program
The Sunshine Act: Reporting for Clinical Trials
Life Sciences Clinical | Biotechnology | Laboratory
Get Instant Access 60 Minutes
View Program